<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01821729</url>
  </required_header>
  <id_info>
    <org_study_id>13-051</org_study_id>
    <nct_id>NCT01821729</nct_id>
  </id_info>
  <brief_title>Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer</brief_title>
  <official_title>Phase II Feasibility Study of FOLFIRINOX-Losartan Followed by Accelerated Short Course Radiation Therapy With Capecitabine for Locally Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II clinical trial, which tests the safety and effectiveness of an
      investigational combination of drugs to learn whether the combination of drugs works in
      treating a specific cancer. &quot;Investigational&quot; means that the combination of drugs is being
      studied. It also means that the FDA has not yet approved it for your type of cancer. Proton
      beam radiation therapy is an FDA approved radiation delivery system.

      Conventional radiation therapy uses photons to treat cancer before patients undergo surgery
      to remove the tumor. In this study we are using radiation with protons, which spares
      surrounding tissue and organs from radiation. Proton radiation delivers radiation to the area
      requiring radiation with no dose beyond the treatment area. This may reduce side effects that
      patients would normally experience with conventional radiation therapy.

      Researchers in the laboratory have discovered pathways inside cancer cells which contribute
      to the growth and survival of tumors. The FOLFIRINOX chemotherapy regimen is a combination of
      the drugs 5-fluorouracil, leucovorin and oxaliplatin. These chemotherapy drugs, along with
      the chemotherapy drug capecitabine, work by blocking these pathways and thereby preventing
      tumor growth. Capecitabine is FDA approved to be used alone or with other drugs to treat
      other types of advanced cancer, but not pancreatic cancer. In past research studies,
      FOLFIRINOX followed by radiation therapy with capecitabine has been identified as the most
      effective and active chemotherapy for patients with cancer that is spreading, and this is why
      we are using it to treat your type of cancer.

      Losartan is classified as an angiotensin-receptor blocker (ARB), and is FDA approved for use
      in people with high blood pressure. Recent studies in people with different types of cancer,
      including pancreatic cancer, have shown that combining chemotherapy drugs with an ARB can
      help reduce/stop tumor growth more effectively than chemotherapy alone. Losartan has been
      used in previous research studies, and information from those research studies suggests that
      this drug in combination with FOLFIRINOX and capecitabine may be better at treating your type
      of cancer.

      In this research study, we seek to determine whether combining FOLFIRINOX with Losartan
      before proton radiation therapy will be more efficient at controlling the growth of or
      shrinking your tumor than just FOLFIRINOX alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      If you are willing to participate in this research study, you will be asked to undergo some
      screening tests and procedures to confirm that you are eligible. Many of these tests and
      procedures are likely to be part of regular cancer care and may be done even if it turns out
      that you do not take part in the research study. If you have had some of these tests or
      procedures recently, they may or may not have to be repeated. These tests and procedures will
      include a medical history, routine physical exam, performance status, assessment of your
      tumor, routine blood tests, a blood sample to check your kidney function and a serum or urine
      pregnancy test if applicable. If these tests show that you are eligible to participate in the
      research study, you will begin the study treatment. If you do not meet the eligibility
      criteria, you will not be able to participate in this research study.

      There are two phases to this study. Phase I involves FOLFIRINOX and Losartan. The treatment
      plant will begin with 8 cycles of FOLFIRINOX. Each cycle is 14 days, or 2 weeks long.
      FOLFIRINOX is comprised of four drugs: Oxaliplatin, irinotecan, fluorouracil and leucovorin.
      On Day 1 of each 14 day cycle, you will receive oxaliplatin via IV infusion over a period of
      2 hours. Irinotecan will be administered via IV infusion on Day 1 of each cycle over a period
      of 90 minutes.

      You will receive fluorouracil (5FU) on Day 1 of each cycle via IV infusion over a period of
      2-4 minutes. You will then be fitted with an ambulatory infusion pump that will be delivered
      continuously over 46-48 hours.

      In addition to these infusions, FOLFIRINOX will always be administered along with a two hours
      IV infusion of leucovorin, a drug composed of reduced folic acid, which helps enhance the
      effects of chemotherapy. You will be give leucovorin through a vein in your arm for 2 hours a
      day on Day 1 of each cycle.

      You will also receive an injection of Neulasta after each FOLFIRINOX treatment. Neulasta is
      used to reduce the chance of infection from chemotherapy by boosting your white blood cell
      count. It will be administered 24-48 hours after your FOLFIRINOX infusion (on Day 3 or 4).

      You will take one dose of Losartan by mouth every day during Phase I for all 8 cycles of
      FOLFIRINOX. If the dose of Losartan given to you during the first week does not give you any
      serious side effects, your dose will be increased once for the remainder of Phase I. We have
      provided a drug diary for you with instructions on how to take this tablet and what to do
      incase of any missed or vomited doses. We will monitor your response to treatment with a
      chest/abdominal CT after four cycles of FOLFIRINOX therapy (8 weeks).

      Phase II involves Restaging/Proton Beam Radiation Therapy and Capecitabine. At this time your
      study doctor will assess for any progress in your cancer after the FOLFIRINOX + Losartan
      treatment again via CT scan. If your cancer has progressed, you will be removed from the
      study and continue with standard of care treatment. If it has not progressed, you will
      continue to the proton radiation therapy and capecitabine phase of the study.

      During this phase you will receive proton beam radiation therapy at the Francis H. Burr
      Proton Therapy center for 1 week, Monday through Friday. Each visit is expected to take 30-45
      minutes.

      During the week of proton radiation therapy and for the week after, you will take
      capecitabine by mouth on Monday through Friday, for a total of ten days. You will be given a
      drug diary with instructions on how to take capecitabine and what to do in case of a missed
      or vomited dose.

      You will receive the following tests and procedures at various time points during both
      portions of the study. These tests and procedures will include: routine blood tests, blood
      sample to check kidney function, CA19-9 and CEA blood tests, Chest CT/Abdominal-Pelvic CT,
      assessment for side effects, vital signs, performance status, routine physical exam and blood
      pressure monitoring.

      After the final dose of study drug you will come into the clinic for follow-up visits for
      some assessments every 3 months until your cancer progresses. You will undergo the following
      tests: routine physical exam, vital signs, performance status, routine blood tests,
      assessment for side effects. In addition you are required to have a chest and
      abdominal/pelvic CT every 6 months for the first two years, and yearly for years 3-5. We
      would like to keep track of your medical condition for the rest of your life. We would like
      to do this by calling you on the telephone once a year to see how you are doing. Keeping in
      touch with you and checking on your condition every year helps us look at the long term
      effects of the research study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Actual">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With R0 Resection</measure>
    <time_frame>At the time of surgery (approximately 4 months after the start of treatment)</time_frame>
    <description>The number of participants that received treatment with proton radiation along with FOLFIRINOX-Losartan and then subsequently underwent attempted surgery and achieved R0 resection. R0 resection means that no cancer cells were seen microscopically at the resection margin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>From the start of treatment until death or progression, median duration of 17.5 months</time_frame>
    <description>To determine the progression free survival of patients with locally advanced disease who receive FOLFIRINOX-Losartan and proton beam radiation therapy. Disease progression was assessed using Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
Progressive disease (PD): At least a 20% increase in the sum of the longest diameter (LD) of target lesion, taking as reference the smal lest sum LD recorded since the treatment started or the appearance of one or more new lesions (new lesions must be &gt; slice thickness).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival for FOLFIRINOX + Proton Beam Radiation</measure>
    <time_frame>2 years</time_frame>
    <description>To determine overall survival in patients treated with preoperative FOLFIRINOX and proton beam radiation therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival for FOLFIRINOX Without Proton Radiation</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the overall survival of patients with locally advanced disease who receive FOLFIRINOX-Losartan without proton radiation (i.e. patients who demonstrate progression at restaging)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine Toxicity FOLFIRINOX-Losartan</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the toxicity of FOLFIRINOX-Losartan in patients with locally advanced pancreatic disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine Toxicity of FOLFIRINOX-Losartan and Proton Beam Radiation</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the toxicity of FOLFIRINOX-Losartan and proton beam radiation in patients with locally advanced pancreatic cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Downstaging</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the rate of downstaging to surgical resection of FOLFIRINOX-Losartan followed by proton radiation in patients with locally advanced pancreatic cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine Correlation of Somatic Gene Mutations and Outcome</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the correlation between a panel of somatic genetic mutations (SNaPSHOT) and outcome in locally advanced pancreatic cancer treated with FOLFIRINOX-Losartan +/- proton beam radiation/capecitabine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine Correlation Between Circulating Biomarkers and Outcome</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the correlation between circulating biomarkers of TGF-B1 downregulation, including circulating Collagen I levels, and outcome in locally advanced pancreatic cancer treated with FOLFIRINOX-Losartan +/- proton beam radiation/capecitabine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe Quality of Life, Symptom Burden and Mood</measure>
    <time_frame>2 years</time_frame>
    <description>Describe quality of life, symptom burden and mood in the study population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Measure Utilization of Health Services</measure>
    <time_frame>2 years</time_frame>
    <description>To measure utilization of health services (ER, hospital and ICU visits) in the study population</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFIRINOX, Losartan, Proton Beam Radiation Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRINOX</intervention_name>
    <description>Oxaliplatin via IV on Day 1 over 2 hours; Irinotecan via IV on Day 1 over 90 minutes, 5FU via IV on Day 1 over 2-4 minutes</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <other_name>5-Fluorouracil</other_name>
    <other_name>5FU</other_name>
    <other_name>Leucovorin</other_name>
    <other_name>Oxaliplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Taken orally every day during Phase I for all 8 cycles</description>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton Beam Radiation</intervention_name>
    <description>30-45 minutes per day, daily Monday-Friday</description>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cytologic or histologic proof pancreatic ductal carcinoma

          -  Locally advanced, unresectable disease

          -  Life expectancy of at least 3 months

        Exclusion Criteria:

          -  Evidence of metastatic disease

          -  Pregnant or breastfeeding

          -  Serious concomitant systemic disorders incompatible with the study

          -  Already treated on ACE or ARB therapy for hypertension or renal protection at the time
             of enrollment

          -  Baseline hypotension

          -  Prior chemotherapy, radiation therapy, or biologic therapy for treatment of pancreatic
             tumor

          -  Treatment for other invasive carcinomas within the last 5 years who are greater than
             5% risk of recurrence at the time of eligibility screening (carcinoma in-situ and
             basal cell carcinoma/squamous cell carcinoma of the skin are allowed)

          -  Other serious uncontrolled medical conditions

          -  Lack of physical integrity of the upper gastrointestinal tract or malabsorption
             syndrome

          -  Known, existing coagulopathy

          -  Prior systemic fluoropyrimidine therapy

          -  Participation in any investigational drug study within 4 weeks preceding the start of
             study treatment

          -  History of uncontrolled seizures, central nervous system disorders or psychiatric
             disability judged by the investigator to be clinically significant, precluding
             informed consent or interfering with compliance or oral drug intake

          -  Major surgery, excluding laparoscopy, within 4 weeks of the start of study treatment

          -  Taking cimetidine

          -  Receiving other study agents

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to 5-fluorouracil, irinotecan, oxaliplatin or losartan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theodore Hong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 27, 2013</study_first_submitted>
  <study_first_submitted_qc>March 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2013</study_first_posted>
  <results_first_submitted>August 27, 2019</results_first_submitted>
  <results_first_submitted_qc>August 27, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 17, 2019</results_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Theodore Sunki Hong</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Locally Advanced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Folfirinox</mesh_term>
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 7, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT01821729/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Experimental Arm</title>
          <description>FOLFIRINOX, Losartan, Proton Beam Radiation Therapy
FOLFIRINOX: Oxaliplatin via IV on Day 1 over 2 hours; Irinotecan via IV on Day 1 over 90 minutes, 5FU via IV on Day 1 over 2-4 minutes
Losartan: Taken orally every day during Phase I for all 8 cycles
Proton Beam Radiation: 30-45 minutes per day, daily Monday-Friday</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Chemoradiotherapy</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Underwent Attempted Surgery</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics are reported for all participants that started treatment. One participant withdrew consent prior to the start of study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Experimental Arm</title>
          <description>FOLFIRINOX, Losartan, Proton Beam Radiation Therapy
FOLFIRINOX: Oxaliplatin via IV on Day 1 over 2 hours; Irinotecan via IV on Day 1 over 90 minutes, 5FU via IV on Day 1 over 2-4 minutes
Losartan: Taken orally every day during Phase I for all 8 cycles
Proton Beam Radiation: 30-45 minutes per day, daily Monday-Friday</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="42" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG PS</title>
          <description>Eastern Cooperative Oncology Group Performance Status: Lower scores indicate better functioning of daily activities of living. The score ranges from 0 to 5.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CA19-9 level</title>
          <description>Carbohydrate antigen (CA) 19-9 is a type of antigen released by pancreatic cancer cells. Elevated CA 19-9 is associated with tumor growth.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;35 U/mL (Normal)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 35 U/mL (Elevated)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CEA level</title>
          <description>Carcinoembryonic antigen is a bio-marker that is associated with some types of cancers. Elevated CEA levels can indicate the presence of a tumor.</description>
          <population>CEA levels were not available for one participant</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;3.4 ng/mL (Normal)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥3.4 ng/mL (Elevated)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor site</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Head</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Body</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Tail</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor size</title>
          <units>mm</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" lower_limit="18" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vascular involvement</title>
          <population>Two participants did not have vascular involvement</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Arterial alone</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Venous alone</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Arterial + venous</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With R0 Resection</title>
        <description>The number of participants that received treatment with proton radiation along with FOLFIRINOX-Losartan and then subsequently underwent attempted surgery and achieved R0 resection. R0 resection means that no cancer cells were seen microscopically at the resection margin.</description>
        <time_frame>At the time of surgery (approximately 4 months after the start of treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental Arm</title>
            <description>FOLFIRINOX, Losartan, Proton Beam Radiation Therapy
FOLFIRINOX: Oxaliplatin via IV on Day 1 over 2 hours; Irinotecan via IV on Day 1 over 90 minutes, 5FU via IV on Day 1 over 2-4 minutes
Losartan: Taken orally every day during Phase I for all 8 cycles
Proton Beam Radiation: 30-45 minutes per day, daily Monday-Friday</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With R0 Resection</title>
          <description>The number of participants that received treatment with proton radiation along with FOLFIRINOX-Losartan and then subsequently underwent attempted surgery and achieved R0 resection. R0 resection means that no cancer cells were seen microscopically at the resection margin.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-Free Survival</title>
        <description>To determine the progression free survival of patients with locally advanced disease who receive FOLFIRINOX-Losartan and proton beam radiation therapy. Disease progression was assessed using Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
Progressive disease (PD): At least a 20% increase in the sum of the longest diameter (LD) of target lesion, taking as reference the smal lest sum LD recorded since the treatment started or the appearance of one or more new lesions (new lesions must be &gt; slice thickness).</description>
        <time_frame>From the start of treatment until death or progression, median duration of 17.5 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental Arm</title>
            <description>FOLFIRINOX, Losartan, Proton Beam Radiation Therapy
FOLFIRINOX: Oxaliplatin via IV on Day 1 over 2 hours; Irinotecan via IV on Day 1 over 90 minutes, 5FU via IV on Day 1 over 2-4 minutes
Losartan: Taken orally every day during Phase I for all 8 cycles
Proton Beam Radiation: 30-45 minutes per day, daily Monday-Friday</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival</title>
          <description>To determine the progression free survival of patients with locally advanced disease who receive FOLFIRINOX-Losartan and proton beam radiation therapy. Disease progression was assessed using Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
Progressive disease (PD): At least a 20% increase in the sum of the longest diameter (LD) of target lesion, taking as reference the smal lest sum LD recorded since the treatment started or the appearance of one or more new lesions (new lesions must be &gt; slice thickness).</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" lower_limit="13.9" upper_limit="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival for FOLFIRINOX + Proton Beam Radiation</title>
        <description>To determine overall survival in patients treated with preoperative FOLFIRINOX and proton beam radiation therapy</description>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival for FOLFIRINOX Without Proton Radiation</title>
        <description>To determine the overall survival of patients with locally advanced disease who receive FOLFIRINOX-Losartan without proton radiation (i.e. patients who demonstrate progression at restaging)</description>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determine Toxicity FOLFIRINOX-Losartan</title>
        <description>To determine the toxicity of FOLFIRINOX-Losartan in patients with locally advanced pancreatic disease</description>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determine Toxicity of FOLFIRINOX-Losartan and Proton Beam Radiation</title>
        <description>To determine the toxicity of FOLFIRINOX-Losartan and proton beam radiation in patients with locally advanced pancreatic cancer.</description>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Downstaging</title>
        <description>To determine the rate of downstaging to surgical resection of FOLFIRINOX-Losartan followed by proton radiation in patients with locally advanced pancreatic cancer</description>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determine Correlation of Somatic Gene Mutations and Outcome</title>
        <description>To determine the correlation between a panel of somatic genetic mutations (SNaPSHOT) and outcome in locally advanced pancreatic cancer treated with FOLFIRINOX-Losartan +/- proton beam radiation/capecitabine</description>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determine Correlation Between Circulating Biomarkers and Outcome</title>
        <description>To determine the correlation between circulating biomarkers of TGF-B1 downregulation, including circulating Collagen I levels, and outcome in locally advanced pancreatic cancer treated with FOLFIRINOX-Losartan +/- proton beam radiation/capecitabine.</description>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Describe Quality of Life, Symptom Burden and Mood</title>
        <description>Describe quality of life, symptom burden and mood in the study population</description>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Measure Utilization of Health Services</title>
        <description>To measure utilization of health services (ER, hospital and ICU visits) in the study population</description>
        <time_frame>2 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the start of treatment until 30 days after the end of treatment, up to approximately 2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Experimental Arm</title>
          <description>FOLFIRINOX, Losartan, Proton Beam Radiation Therapy
FOLFIRINOX: Oxaliplatin via IV on Day 1 over 2 hours; Irinotecan via IV on Day 1 over 90 minutes, 5FU via IV on Day 1 over 2-4 minutes
Losartan: Taken orally every day during Phase I for all 8 cycles
Proton Beam Radiation: 30-45 minutes per day, daily Monday-Friday</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="5" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders - Other, specify</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="105" subjects_affected="37" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="72" subjects_affected="32" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="101" subjects_affected="29" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="20" subjects_affected="13" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hemorrhoidal hemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Malabsorption</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="123" subjects_affected="33" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="53" subjects_affected="22" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="23" subjects_affected="13" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="124" subjects_affected="40" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="91" subjects_affected="33" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="80" subjects_affected="36" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="59" subjects_affected="22" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="11" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="33" subjects_affected="19" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder -</sub_title>
                <counts group_id="E1" events="20" subjects_affected="9" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Concentration impairment</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="37" subjects_affected="22" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="18" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="131" subjects_affected="35" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Spasticity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, specify</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="31" subjects_affected="22" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="36" subjects_affected="20" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Urine discoloration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Renal and urinary disorders - Other, specify</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hoarseness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="24" subjects_affected="12" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <counts group_id="E1" events="27" subjects_affected="13" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="28" subjects_affected="16" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Vascular disorders - Other, specify</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Theodore Hong</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-6050</phone>
      <email>TSHONG1@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

